缺氧诱导CEA靶向CAR-T治疗复发IV期非小细胞肺癌
该首次人体I期试验评估缺氧诱导CEA靶向CAR-T在经重度治疗的复发IV期NSCLC患者中的表现,单次输注客观缓解率47%、疾病控制率87%,安全性可控;单细胞分析提示缓解与缺氧适应肿瘤反应性CD8+ T细胞扩增及NK细胞功能成熟相关。
要点
- 缺氧诱导CAR设计将CAR激活限制于缺氧肿瘤微环境以减轻on-target off-tumor毒性。
- 单次输注客观缓解率47%、疾病控制率87%,安全性可控。
- 缓解与缺氧适应肿瘤反应性样CD8+ T细胞扩增及NK细胞协同功能成熟相关。
核心结论
- 缺氧诱导CEA靶向CAR-T在复发IV期NSCLC中显示临床概念验证,支持利用肿瘤微环境特征设计实体瘤细胞免疫治疗。
研究设计与样本
- 首次人体I期试验,纳入经重度治疗的复发IV期NSCLC患者,给予单次缺氧诱导CEA靶向CAR-T输注。
主要发现
- 单次输注客观缓解率为47%,疾病控制率为87%,安全性可控。
- 探索性分析显示临床结局与基线因素相关。
- 深度单细胞分析显示临床缓解与缺氧适应、肿瘤反应性样CD8+ T细胞扩增及NK细胞协同功能成熟相关。
关键数值与推荐
- 客观缓解率47%,疾病控制率87%。
临床怎么用
- 为复发IV期NSCLC经重度治疗患者提供缺氧诱导CEA靶向CAR-T的临床概念验证,支持进一步开发基于肿瘤微环境的实体瘤细胞免疫策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitigating on-target off-tumor toxicity remains a central challenge for chimeric antigen receptor (CAR) T-cell therapy for solid tumors. We developed a hypoxia-inducible CAR-T-cell product targeting carcinoembryonic antigen (CEA) that restricts CAR activation to hypoxic tumor niches via oxygen-dependent expression control. In this first-in-human, phase I trial enrolling heavily pretreated patients with relapsed stage IV non-small cell lung cancer (NSCLC), a single infusion of the investigational product achieved an objective response rate of 47% and a disease control rate of 87%, with a manageable safety profile. Exploratory analyses showed that clinical outcomes were associated with baseline factors. Deep single-cell profiling indicated that the clinical response was associated with the expansion of hypoxia-adapted, tumor-reactive-like CD8+ T cells alongside coordinated functional maturation of natural killer (NK) cells. Collectively, these data provide clinical proof-of-concept for hypoxia-inducible CAR design and inform the rational development of strategies leveraging tumor microenvironmental features in solid tumor cellular immunotherapy.
引用
- Wei, Guo, Bai, et al. Hypoxia-inducible CEA-targeted CAR T-cell therapy for relapsed stage IV non-small cell lung cancer. Cancer Discov. 2026. PMID: 42937295. doi:10.1158/2159-8290.CD-26-0104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。